JP2008539215A5 - - Google Patents

Download PDF

Info

Publication number
JP2008539215A5
JP2008539215A5 JP2008508290A JP2008508290A JP2008539215A5 JP 2008539215 A5 JP2008539215 A5 JP 2008539215A5 JP 2008508290 A JP2008508290 A JP 2008508290A JP 2008508290 A JP2008508290 A JP 2008508290A JP 2008539215 A5 JP2008539215 A5 JP 2008539215A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
optionally substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008508290A
Other languages
English (en)
Japanese (ja)
Other versions
JP5243953B2 (ja
JP2008539215A (ja
Filing date
Publication date
Priority claimed from GBGB0508471.0A external-priority patent/GB0508471D0/en
Application filed filed Critical
Publication of JP2008539215A publication Critical patent/JP2008539215A/ja
Publication of JP2008539215A5 publication Critical patent/JP2008539215A5/ja
Application granted granted Critical
Publication of JP5243953B2 publication Critical patent/JP5243953B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008508290A 2005-04-26 2006-04-25 キナーゼ阻害剤としての縮合チアゾール誘導体 Expired - Fee Related JP5243953B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0508471.0 2005-04-26
GBGB0508471.0A GB0508471D0 (en) 2005-04-26 2005-04-26 Therapeutic agents
PCT/GB2006/001505 WO2006114606A1 (en) 2005-04-26 2006-04-25 Fused thiazole derivatives as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2008539215A JP2008539215A (ja) 2008-11-13
JP2008539215A5 true JP2008539215A5 (cg-RX-API-DMAC7.html) 2012-08-30
JP5243953B2 JP5243953B2 (ja) 2013-07-24

Family

ID=34640185

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008508290A Expired - Fee Related JP5243953B2 (ja) 2005-04-26 2006-04-25 キナーゼ阻害剤としての縮合チアゾール誘導体

Country Status (9)

Country Link
US (1) US7888344B2 (cg-RX-API-DMAC7.html)
EP (1) EP1881827B1 (cg-RX-API-DMAC7.html)
JP (1) JP5243953B2 (cg-RX-API-DMAC7.html)
AT (1) ATE526021T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006239018B2 (cg-RX-API-DMAC7.html)
CA (1) CA2607426C (cg-RX-API-DMAC7.html)
ES (1) ES2373680T3 (cg-RX-API-DMAC7.html)
GB (1) GB0508471D0 (cg-RX-API-DMAC7.html)
WO (1) WO2006114606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001076A1 (en) 2006-06-26 2008-01-03 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
WO2009001089A1 (en) * 2007-06-26 2008-12-31 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
GB0620818D0 (en) * 2006-10-19 2006-11-29 Ucb Sa Therapeutic agents
CA2669886A1 (en) 2006-11-15 2008-05-22 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinase inhibitors
RU2478387C2 (ru) 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
ATE510841T1 (de) 2007-06-12 2011-06-15 Hoffmann La Roche Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
WO2009036768A2 (en) * 2007-09-19 2009-03-26 H. Lundbeck A/S Diagnosing potential weight gain in a subject
CN101932587A (zh) 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
GB0723747D0 (en) * 2007-12-04 2008-12-31 Ucb Pharma Sa Therapeutic agents
WO2009094224A1 (en) 2008-01-25 2009-07-30 Millennium Pharmaceuticals, Inc. Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
WO2009120826A1 (en) * 2008-03-27 2009-10-01 Wyeth 2-aryl- and 2-heteroarylthiazolyl compounds, methods for their preparation and use thereof
GB0805818D0 (en) * 2008-03-31 2008-04-30 Ucb Pharma Sa Therapeutic agents
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2012516329A (ja) 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ, インコーポレイテッド Pi3k阻害剤としてのヘテロアリールおよびその使用
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
ES2638323T3 (es) 2009-05-20 2017-10-19 Glaxosmithkline Llc Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa
SG182247A1 (en) 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
MX2011012520A (es) 2009-05-27 2011-12-12 Hoffmann La Roche Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos.
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US8859768B2 (en) 2010-08-11 2014-10-14 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2603214A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc HETEROARYLE AND USES THEREOF
MX2013004003A (es) * 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
AU2012226375B2 (en) 2011-03-10 2017-04-13 Lupin Atlantis Holdings Sa Substituted morpholines as modulators for the calcium sensing receptor
TWI710558B (zh) 2013-05-01 2020-11-21 瑞士商赫孚孟拉羅股份公司 二雜芳基化合物及其用途
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN107556199A (zh) * 2017-09-24 2018-01-09 杨子辉 一种3,4‑二氯‑2‑氨基‑5‑氟联苯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357099A1 (en) * 2000-02-07 2004-07-12 Abbott Gmbh & Co.Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US7176214B2 (en) * 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same

Similar Documents

Publication Publication Date Title
JP2008538557A5 (cg-RX-API-DMAC7.html)
JP2009515872A5 (cg-RX-API-DMAC7.html)
JP2010504286A5 (cg-RX-API-DMAC7.html)
JP2007508359A5 (cg-RX-API-DMAC7.html)
JP2008510828A5 (cg-RX-API-DMAC7.html)
JP2005523310A5 (cg-RX-API-DMAC7.html)
WO2005037781A3 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
JP2005529954A5 (cg-RX-API-DMAC7.html)
JP2008044952A5 (cg-RX-API-DMAC7.html)
JP2014507464A5 (cg-RX-API-DMAC7.html)
JP2010504908A5 (cg-RX-API-DMAC7.html)
JP2007500753A5 (cg-RX-API-DMAC7.html)
JP2012510502A5 (cg-RX-API-DMAC7.html)
WO2008006043A3 (en) 1,3-oxazole derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents
JP2010519270A5 (cg-RX-API-DMAC7.html)
CA2683059A1 (en) Atropisomer of pyrrole derivative
JP2013502441A5 (cg-RX-API-DMAC7.html)
JP2009504793A5 (cg-RX-API-DMAC7.html)
JP2008519084A5 (cg-RX-API-DMAC7.html)
JP2009184932A5 (cg-RX-API-DMAC7.html)
JP2013544854A5 (cg-RX-API-DMAC7.html)
JP2013515037A5 (cg-RX-API-DMAC7.html)
JP2004525183A5 (cg-RX-API-DMAC7.html)
JP2004525184A5 (cg-RX-API-DMAC7.html)
JP2008513472A5 (cg-RX-API-DMAC7.html)